Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines

R. N. Daly, A. C. Sulpizio, B. Levitt, R. M. DeMarinis, John W Regan, R. R. Ruffolo, J. P. Hieble

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

A series of alpha adrenoceptor antagonists, including both reference compounds and the novel benzazepine antagonists, SK&F 86466 (6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine) and two of its 9-substituted derivatives, SK&F 101253 and SK&F 104078, were tested in vitro for affinity at central and peripheral alpha adrenoceptor subtypes. Peripheral alpha-1 adrenoceptor antagonist potency of these agents, as assessed by the receptor dissociation constant (K(B)) against norepinephrine-induced contraction in the rabbit aorta, correlated with the K(i) value for inhibition of [3H]prazosin binding to central alpha-1 adrenoceptors in rat brain homogenates. Central alpha-2 adrenoceptor affinity, measured as the K(i) for inhibition of [3H]rauwolscine binding to rat brain homogenates, correlated well with antagonist activity at peripheral postjunctional alpha-2 adrenoceptors as reflected by the K(B) against B-HT 920-induced contraction in canine saphenous vein. The 9-substituted benzazepines, SK&F 101253 and SK&F 104078, produce preferential blockade of postjunctional vs. prejunctional alpha-2 adrenoceptors in peripheral models. The high affinity of SK&F 104078 for postjunctional alpha-2 adrenoceptors in the canine saphenous vein was confirmed by its ability to inhibit [3H]rauwolscine binding to postjunctional alpha-2 adrenoceptors in this tissue. The observation that the K(i) values for these antagonists against [3H]rauwolscine binding correlate with their K(B) values at the postjunctional alpha-2 adrenoceptors, rather than those at the postjunctional neuroinhibitory alpha-2 adrenoceptor, suggests a pharmacologic similarity between the postjunctional vascular alpha-2 adrenoceptors and the central [3H]rauwolcine binding site. SK&F 104078, the most selective postjunctional vis-a-vis prejunctional alpha-2 adrenoceptor antagonist in the series, inhibited the binding of [3H]yohimbine to human platelet membranes with a K(i) nearly identical to that observed in rat brain, suggesting that the platelet alpha-2 adrenoceptor is also similar to that in the rat brain and canine saphenous vein. The results indicate that selective postjunctional alpha-2 adrenoceptor antagonists may represent novel and useful pharmacologic tools with which to subclassify alpha adrenoceptors.

Original languageEnglish (US)
Pages (from-to)122-128
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume247
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Benzazepines
Adrenergic Receptors
Yohimbine
Saphenous Vein
Canidae
Brain
Blood Platelets

ASJC Scopus subject areas

  • Pharmacology

Cite this

Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines. / Daly, R. N.; Sulpizio, A. C.; Levitt, B.; DeMarinis, R. M.; Regan, John W; Ruffolo, R. R.; Hieble, J. P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 247, No. 1, 1988, p. 122-128.

Research output: Contribution to journalArticle

Daly, R. N. ; Sulpizio, A. C. ; Levitt, B. ; DeMarinis, R. M. ; Regan, John W ; Ruffolo, R. R. ; Hieble, J. P. / Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines. In: Journal of Pharmacology and Experimental Therapeutics. 1988 ; Vol. 247, No. 1. pp. 122-128.
@article{e411adc42ede481db2fa145a423c3366,
title = "Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines",
abstract = "A series of alpha adrenoceptor antagonists, including both reference compounds and the novel benzazepine antagonists, SK&F 86466 (6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine) and two of its 9-substituted derivatives, SK&F 101253 and SK&F 104078, were tested in vitro for affinity at central and peripheral alpha adrenoceptor subtypes. Peripheral alpha-1 adrenoceptor antagonist potency of these agents, as assessed by the receptor dissociation constant (K(B)) against norepinephrine-induced contraction in the rabbit aorta, correlated with the K(i) value for inhibition of [3H]prazosin binding to central alpha-1 adrenoceptors in rat brain homogenates. Central alpha-2 adrenoceptor affinity, measured as the K(i) for inhibition of [3H]rauwolscine binding to rat brain homogenates, correlated well with antagonist activity at peripheral postjunctional alpha-2 adrenoceptors as reflected by the K(B) against B-HT 920-induced contraction in canine saphenous vein. The 9-substituted benzazepines, SK&F 101253 and SK&F 104078, produce preferential blockade of postjunctional vs. prejunctional alpha-2 adrenoceptors in peripheral models. The high affinity of SK&F 104078 for postjunctional alpha-2 adrenoceptors in the canine saphenous vein was confirmed by its ability to inhibit [3H]rauwolscine binding to postjunctional alpha-2 adrenoceptors in this tissue. The observation that the K(i) values for these antagonists against [3H]rauwolscine binding correlate with their K(B) values at the postjunctional alpha-2 adrenoceptors, rather than those at the postjunctional neuroinhibitory alpha-2 adrenoceptor, suggests a pharmacologic similarity between the postjunctional vascular alpha-2 adrenoceptors and the central [3H]rauwolcine binding site. SK&F 104078, the most selective postjunctional vis-a-vis prejunctional alpha-2 adrenoceptor antagonist in the series, inhibited the binding of [3H]yohimbine to human platelet membranes with a K(i) nearly identical to that observed in rat brain, suggesting that the platelet alpha-2 adrenoceptor is also similar to that in the rat brain and canine saphenous vein. The results indicate that selective postjunctional alpha-2 adrenoceptor antagonists may represent novel and useful pharmacologic tools with which to subclassify alpha adrenoceptors.",
author = "Daly, {R. N.} and Sulpizio, {A. C.} and B. Levitt and DeMarinis, {R. M.} and Regan, {John W} and Ruffolo, {R. R.} and Hieble, {J. P.}",
year = "1988",
language = "English (US)",
volume = "247",
pages = "122--128",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines

AU - Daly, R. N.

AU - Sulpizio, A. C.

AU - Levitt, B.

AU - DeMarinis, R. M.

AU - Regan, John W

AU - Ruffolo, R. R.

AU - Hieble, J. P.

PY - 1988

Y1 - 1988

N2 - A series of alpha adrenoceptor antagonists, including both reference compounds and the novel benzazepine antagonists, SK&F 86466 (6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine) and two of its 9-substituted derivatives, SK&F 101253 and SK&F 104078, were tested in vitro for affinity at central and peripheral alpha adrenoceptor subtypes. Peripheral alpha-1 adrenoceptor antagonist potency of these agents, as assessed by the receptor dissociation constant (K(B)) against norepinephrine-induced contraction in the rabbit aorta, correlated with the K(i) value for inhibition of [3H]prazosin binding to central alpha-1 adrenoceptors in rat brain homogenates. Central alpha-2 adrenoceptor affinity, measured as the K(i) for inhibition of [3H]rauwolscine binding to rat brain homogenates, correlated well with antagonist activity at peripheral postjunctional alpha-2 adrenoceptors as reflected by the K(B) against B-HT 920-induced contraction in canine saphenous vein. The 9-substituted benzazepines, SK&F 101253 and SK&F 104078, produce preferential blockade of postjunctional vs. prejunctional alpha-2 adrenoceptors in peripheral models. The high affinity of SK&F 104078 for postjunctional alpha-2 adrenoceptors in the canine saphenous vein was confirmed by its ability to inhibit [3H]rauwolscine binding to postjunctional alpha-2 adrenoceptors in this tissue. The observation that the K(i) values for these antagonists against [3H]rauwolscine binding correlate with their K(B) values at the postjunctional alpha-2 adrenoceptors, rather than those at the postjunctional neuroinhibitory alpha-2 adrenoceptor, suggests a pharmacologic similarity between the postjunctional vascular alpha-2 adrenoceptors and the central [3H]rauwolcine binding site. SK&F 104078, the most selective postjunctional vis-a-vis prejunctional alpha-2 adrenoceptor antagonist in the series, inhibited the binding of [3H]yohimbine to human platelet membranes with a K(i) nearly identical to that observed in rat brain, suggesting that the platelet alpha-2 adrenoceptor is also similar to that in the rat brain and canine saphenous vein. The results indicate that selective postjunctional alpha-2 adrenoceptor antagonists may represent novel and useful pharmacologic tools with which to subclassify alpha adrenoceptors.

AB - A series of alpha adrenoceptor antagonists, including both reference compounds and the novel benzazepine antagonists, SK&F 86466 (6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine) and two of its 9-substituted derivatives, SK&F 101253 and SK&F 104078, were tested in vitro for affinity at central and peripheral alpha adrenoceptor subtypes. Peripheral alpha-1 adrenoceptor antagonist potency of these agents, as assessed by the receptor dissociation constant (K(B)) against norepinephrine-induced contraction in the rabbit aorta, correlated with the K(i) value for inhibition of [3H]prazosin binding to central alpha-1 adrenoceptors in rat brain homogenates. Central alpha-2 adrenoceptor affinity, measured as the K(i) for inhibition of [3H]rauwolscine binding to rat brain homogenates, correlated well with antagonist activity at peripheral postjunctional alpha-2 adrenoceptors as reflected by the K(B) against B-HT 920-induced contraction in canine saphenous vein. The 9-substituted benzazepines, SK&F 101253 and SK&F 104078, produce preferential blockade of postjunctional vs. prejunctional alpha-2 adrenoceptors in peripheral models. The high affinity of SK&F 104078 for postjunctional alpha-2 adrenoceptors in the canine saphenous vein was confirmed by its ability to inhibit [3H]rauwolscine binding to postjunctional alpha-2 adrenoceptors in this tissue. The observation that the K(i) values for these antagonists against [3H]rauwolscine binding correlate with their K(B) values at the postjunctional alpha-2 adrenoceptors, rather than those at the postjunctional neuroinhibitory alpha-2 adrenoceptor, suggests a pharmacologic similarity between the postjunctional vascular alpha-2 adrenoceptors and the central [3H]rauwolcine binding site. SK&F 104078, the most selective postjunctional vis-a-vis prejunctional alpha-2 adrenoceptor antagonist in the series, inhibited the binding of [3H]yohimbine to human platelet membranes with a K(i) nearly identical to that observed in rat brain, suggesting that the platelet alpha-2 adrenoceptor is also similar to that in the rat brain and canine saphenous vein. The results indicate that selective postjunctional alpha-2 adrenoceptor antagonists may represent novel and useful pharmacologic tools with which to subclassify alpha adrenoceptors.

UR - http://www.scopus.com/inward/record.url?scp=0023774945&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023774945&partnerID=8YFLogxK

M3 - Article

C2 - 2902209

AN - SCOPUS:0023774945

VL - 247

SP - 122

EP - 128

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -